| |
Female patients
(n=156) |
Male patients
(n=69) |
Patients with CR or PR [7]:
- Spontaneous response or after first-line therapy (steroids, IgIV)
- After second-line therapy (splenectomy, rituximab) |
56 (35.9%)
44 (28.2%) |
26 (37.7%)
21 (30.4%) |
| Patients with chronic ITP requiring long-term drug use (steroids, danazol, etc.) due to recurrent and chronic bleeding and/or low platelet counts |
39 (25%) |
19 (27.5%) |
| Patients with chronic ITP and PR or F [7] managed with a ‘wait-and-see’ policy and punctual treatment |
14 (9%) |
6 (8.7%) |
| IgIV: intravenous immunoglobulins. CR: complete response (platelet count >150 x 109/l after treatment). PR: partial response (platelet count of 50 to 150 ×109/l or platelet levels twofold higher after treatment if the initial platelet count was <50 ×109/l). F: failure. |
